Baseline biomarker status demonstrated that 31 patients (30.1%) were HR positive, 19 (18.4%) were both HR and HER2/neu receptor positive, 24 (23.3%) were HER2/neu receptor only positive, and 29 (28.2%) were triple-negative breast cancer as listed in Table 2. Here, ERBB2 is linked to triple-negative breast carcinoma.